Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is being conducted to assess mechanistic blood biomarkers of CAT-1004 in healthy humans.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CAT-1004 Dose #1 | Experimental | Single dose #1 |
|
| Salsalate + DHA | Active Comparator | Single dose #2 |
|
| Placebo | Placebo Comparator | Single Dose #3 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CAT-1004 | Drug |
| ||
| Salsalate + DHA |
| Measure | Description | Time Frame |
|---|---|---|
| Change in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activity p65 following ex vivo lipopolysaccharide stimulation | Pre/post each of 3 Single doses |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Other biomarkers including select cytokines and RNA gene expression may also be assessed | Pre/post each of 3 Single doses |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joanne Donovan, MD, PhD | Catabasis | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ProMedica | Brighton | Massachusetts | 02135 | United States |
Not provided
| ID | Term |
|---|---|
| C000622102 | edasalonexent |
| C014182 | salicylsalicylic acid |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug |
|